nach oben

Erschienen in:

01.12.2014 | Schwerpunkt

ESC/EACTS-Leitlinie zur Revaskularisation des Myokards

Veränderungen 2014

verfasst von: Prof. Dr. H. Nef, M. Renker, C.W. Hamm

Erschienen in: Herz | Ausgabe 8/2014

Einloggen, um Zugang zu erhalten

Zusammenfassung

Eines der wichtigsten Behandlungsprinzipien in der Kardiologie ist die myokardiale Revaskularisierung entweder durch eine perkutane Koronarintervention oder durch eine Bypass-Operation. Um diese Behandlungsprinzipien effektiv einzusetzen, ist es erforderlich, die Patienten zu identifizieren, bei denen eine Revaskularisierung erforderlich ist. Ebenso ist die Auswahl der geeigneten Revaskularisationsmethode von entscheidender Bedeutung. Nur dann wird der größtmögliche Nutzen ohne Gefährdung des Patienten erzielt. In den neuen ESC/EACTS-Leitlinien zur myokardialen Revaskularisierung ergeben sich einige klinisch relevante neue Aspekte, die in dieser Übersicht zusammengefasst werden.

Nabel EG, Braunwald E (2012) A tale of coronary artery disease and myocardial infarction. N Engl J Med 366:54–63PubMedCrossRef

Fuster V, Mearns BM (2009) The CVD paradox: mortality vs prevalence. Nat Rev Cardiol 6:669PubMedCrossRef

Olearchyk AS (1988) Vasilii I. Kolesov. A pioneer of coronary revascularization by internal mammary-coronary artery grafting. J Thorac Cardiovasc Surg 96:13–18PubMed

Garrett HE, Dennis EW, DeBakey ME (1973) Aortocoronary bypass with saphenous vein graft. Seven-year follow-up. JAMA 223:792–794PubMedCrossRef

Gruentzig A (1978) Transluminal dilatation of coronary-artery stenosis. Lancet 1:263CrossRef

Fox KA, Clayton TC, Damman P et al (2010) Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data. J Am Coll Cardiol 55:2435–2445PubMedCrossRef

Keeley EC, Boura JA, Grines CL (2003) Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 361:13–20PubMedCrossRef

Windecker S, Stortecky S, Stefanini GG et al (2014) Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ 348:g3859PubMedCentralPubMedCrossRef

Stefanini GG, Holmes DR Jr (2013) Drug-eluting coronary-artery stents. N Engl J Med 368:254–265PubMedCrossRef

10.

Windecker S, Kolh P, Alfonso F et al (2014) 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35:2541–2619PubMedCrossRef

11.

Wijns W, Kolh P, Danchin N et al (2010) Guidelines on myocardial revascularization. Eur Heart J 31:2501–2555PubMedCrossRef

12.

Head SJ, Kaul S, Mack MJ et al (2013) The rationale for Heart Team decision-making for patients with stable, complex coronary artery disease. Eur Heart J 34:2510–2518PubMedCrossRef

13.

Shahian DM, O’Brien SM, Filardo G et al (2009) The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 3 – valve plus coronary artery bypass grafting surgery. Ann Thorac Surg 88:S43–S62PubMedCrossRef

14.

Shahian DM, O’Brien SM, Filardo G et al (2009) The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 1 – coronary artery bypass grafting surgery. Ann Thorac Surg 88:S2–S22PubMedCrossRef

15.

Nashef SA, Roques F, Sharples LD et al (2012) EuroSCORE II. Eur J Cardiothorac Surg 41:734–744PubMedCrossRef

16.

Biancari F, Vasques F, Mikkola R et al (2012) Validation of EuroSCORE II in patients undergoing coronary artery bypass surgery. Ann Thorac Surg 93:1930–1935PubMedCrossRef

17.

Chalmers J, Pullan M, Fabri B et al (2013) Validation of EuroSCORE II in a modern cohort of patients undergoing cardiac surgery. Eur J Cardiothorac Surg 43:688–694PubMedCrossRef

18.

Siregar S, Groenwold RH, Heer F de et al (2012) Performance of the original EuroSCORE. Eur J Cardiothorac Surg 41:746–754PubMedCrossRef

19.

Hickey GL, Grant SW, Murphy GJ et al (2013) Dynamic trends in cardiac surgery: why the logistic EuroSCORE is no longer suitable for contemporary cardiac surgery and implications for future risk models. Eur J Cardiothorac Surg 43:1146–1152PubMedCentralPubMedCrossRef

20.

Mohr FW, Rastan AJ, Serruys PW et al (2011) Complex coronary anatomy in coronary artery bypass graft surgery: impact of complex coronary anatomy in modern bypass surgery? Lessons learned from the SYNTAX trial after two years. J Thorac Cardiovasc Surg 141:130–140PubMedCrossRef

21.

Mohr FW, Morice MC, Kappetein AP et al (2013) Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 381:629–638PubMedCrossRef

22.

Genereux P, Palmerini T, Caixeta A et al (2011) SYNTAX score reproducibility and variability between interventional cardiologists, core laboratory technicians, and quantitative coronary measurements. Circ Cardiovasc Interv 4:553–561PubMedCrossRef

23.

Farooq V, Vergouwe Y, Raber L et al (2012) Combined anatomical and clinical factors for the long-term risk stratification of patients undergoing percutaneous coronary intervention: the Logistic Clinical SYNTAX score. Eur Heart J 33:3098–3104PubMedCrossRef

24.

Farooq V, Klaveren D van, Steyerberg EW et al (2013) Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet 381:639–650PubMedCrossRef

25.

Papadopoulou SL, Girasis C, Dharampal A et al (2013) CT-SYNTAX score: a feasibility and reproducibility Study. JACC Cardiovasc Imaging 6:413–415PubMedCrossRef

26.

Peterson ED, Dai D, DeLong ER et al (2010) Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry. J Am Coll Cardiol 55:1923–1932PubMedCentralPubMedCrossRef

27.

Ranucci M, Castelvecchio S, Menicanti L et al (2009) Risk of assessing mortality risk in elective cardiac operations: age, creatinine, ejection fraction, and the law of parsimony. Circulation 119:3053–3061PubMedCrossRef

28.

Wykrzykowska JJ, Garg S, Onuma Y et al (2011) Value of age, creatinine, and ejection fraction (ACEF score) in assessing risk in patients undergoing percutaneous coronary interventions in the ‚All-Comers‘ LEADERS trial. Circ Cardiovasc Interv 4:47–56PubMedCrossRef

29.

Weintraub WS, Grau-Sepulveda MV, Weiss JM et al (2012) Comparative effectiveness of revascularization strategies. N Engl J Med 366:1467–1476PubMedCrossRef

30.

Shahian DM, O’Brien SM, Sheng S et al (2012) Predictors of long-term survival after coronary artery bypass grafting surgery: results from the Society of Thoracic Surgeons Adult Cardiac Surgery Database (the ASCERT study). Circulation 125:1491–1500PubMedCentralPubMedCrossRef

31.

Weintraub WS, Grau-Sepulveda MV, Weiss JM et al (2012) Prediction of long-term mortality after percutaneous coronary intervention in older adults: results from the National Cardiovascular Data Registry. Circulation 125:1501–1510PubMedCentralPubMedCrossRef

32.

Graham MM, Knudtson ML, O’Neill BJ, Ross DB (2006) Treating the right patient at the right time: access to cardiac catheterization, percutaneous coronary intervention and cardiac surgery. Can J Cardiol 22:679–683PubMedCentralPubMedCrossRef

33.

Sobolev BG, Fradet G, Kuramoto L, Rogula B (2013) The occurrence of adverse events in relation to time after registration for coronary artery bypass surgery: a population-based observational study. J Cardiothorac Surg 8:74PubMedCentralPubMedCrossRef

34.

Montalescot G, Sechtem U, Achenbach S et al (2013) 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 34:2949–3003PubMedCrossRef

35.

De Bruyne B, Pijls NH, Kalesan B et al (2012) Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med 367:991–1001CrossRef

36.

Tonino PA, De Bruyne B, Pijls NH et al (2009) Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 360:213–224PubMedCrossRef

37.

Pijls NH, Schaardenburgh P van, Manoharan G et al (2007) Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. J Am Coll Cardiol 49:2105–2111PubMedCrossRef

38.

Yusuf S, Zucker D, Peduzzi P et al (1994) Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 344:563–570PubMedCrossRef

39.

Morice MC, Serruys PW, Kappetein AP et al (2010) Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial. Circulation 121:2645–2653PubMedCrossRef

40.

Morice MC, Serruys PW, Kappetein AP et al (2014) Five-year outcomes in patients with left main disease treated with either percutaneous coronary intervention or coronary artery bypass grafting in the synergy between percutaneous coronary intervention with taxus and cardiac surgery trial. Circulation 129:2388–2394PubMedCrossRef

41.

Farkouh ME, Domanski M, Sleeper LA et al (2012) Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 367:2375–2384PubMedCrossRef

42.

Kappetein AP, Head SJ, Morice MC et al (2013) Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. Eur J Cardiothorac Surg 43:1006–1013PubMedCrossRef

43.

Kapur A, Hall RJ, Malik IS et al (2010) Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. J Am Coll Cardiol 55:432–440PubMedCrossRef

44.

Stettler C, Allemann S, Wandel S et al (2008) Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ 337:a1331PubMedCentralPubMedCrossRef

45.

Bangalore S, Kumar S, Fusaro M et al (2012) Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomised trials. BMJ 345:e5170PubMedCentralPubMedCrossRef

46.

Velazquez EJ, Lee KL, Deja MA et al (2011) Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 364:1607–1616PubMedCentralPubMedCrossRef

47.

Velazquez EJ, Williams JB, Yow E et al (2012) Long-term survival of patients with ischemic cardiomyopathy treated by coronary artery bypass grafting versus medical therapy. Ann Thorac Surg 93:523–530PubMedCentralPubMedCrossRef

48.

Valgimigli M, Campo G, Monti M et al (2012) Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 125:2015–2026PubMedCrossRef

49.

Gwon HC, Hahn JY, Park KW et al (2012) Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation 125:505–513PubMedCrossRef

50.

Kim BK, Hong MK, Shin DH et al (2012) A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol 60:1340–1348PubMedCrossRef

51.

Feres F, Costa RA, Abizaid A et al (2013) Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA 310:2510–2522PubMed

52.

Kedhi E, Stone GW, Kereiakes DJ et al (2012) Stent thrombosis: insights on outcomes, predictors and impact of dual antiplatelet therapy interruption from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE trials. EuroIntervention 8:599–606PubMedCrossRef

53.

Silber S, Kirtane AJ, Belardi JA et al (2014) Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. Eur Heart J 35:1949–1956PubMedCrossRef

54.

Pisters R, Lane DA, Nieuwlaat R et al (2010) A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138:1093–1100PubMedCrossRef

55.

Hamm CW, Bassand JP, Agewall S et al (2011) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 32:2999–3054PubMedCrossRef

56.

Montalescot G, Bolognese L, Dudek D et al (2013) Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med 369:999–1010PubMedCrossRef

57.

Montalescot G, Hof AW van ‚t, Lapostolle F et al (2014) Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 371:1016–1027PubMed

58.

Montalescot G, Lassen JF, Hamm CW et al (2013) Ambulance or in-catheterization laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: rationale and design of the randomized, double-blind Administration of Ticagrelor in the cath Lab or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) study. Am Heart J 165:515–522PubMedCrossRef

Titel: ESC/EACTS-Leitlinie zur Revaskularisation des Myokards
Veränderungen 2014
verfasst von: Prof. Dr. H. Nef
M. Renker
C.W. Hamm
Publikationsdatum: 01.12.2014
Verlag: Urban & Vogel
Erschienen in: Herz / Ausgabe 8/2014
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-014-4180-4

Neu im Fachgebiet Kardiologie

19.04.2024 | Vorhofflimmern | Nachrichten

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

ESC/EACTS-Leitlinie zur Revaskularisation des Myokards

Veränderungen 2014

Zusammenfassung

Neu im Fachgebiet Kardiologie

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Sind Betablocker auch für ältere herzschwache Personen nützlich?

Stillende Frauen haben geringeres kardiovaskuläres Risiko

Update Kardiologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2014

Dehiscence of mitral annuloplasty ring on real-time 3D transesophageal echocardiography

Diagnostik und Therapie der chronisch stabilen koronaren Herzkrankheit

Alle Jahre wieder – Leitlinien 2014

Unsuccessful MitraClip procedure due to emerging right atrial thrombus and difficult transseptal puncture

Thrombin activatable fibrinolysis inhibitor

Aktuelle Kardiologie

Neu im Fachgebiet Kardiologie

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Sind Betablocker auch für ältere herzschwache Personen nützlich?

Stillende Frauen haben geringeres kardiovaskuläres Risiko

Update Kardiologie